Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hightide Therapeutics Inc ( (HK:2511) ) just unveiled an update.
HighTide Therapeutics presented evidence at the ASN Annual Meeting showing that their drug HTD1801 benefits patients with mild renal impairment by improving eGFR trajectory and normalizing renal function. This development highlights HTD1801’s potential as a foundational therapy in CKM disease management, reinforcing the company’s strategic focus on delivering comprehensive treatments for chronic metabolic diseases.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a biopharmaceutical company focused on developing multifunctional, multi-targeted therapies for chronic metabolic diseases, particularly addressing cardiovascular-kidney-metabolic (CKM) syndrome. The company has a globally integrated pipeline and has advanced multiple clinical programs, with its lead asset, HTD1801, receiving Fast Track and Orphan Drug designations from the US FDA.
Average Trading Volume: 1,319,895
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.78B
For an in-depth examination of 2511 stock, go to TipRanks’ Overview page.